TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Outcome following laparoscopic surgery for GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median time to attain the initial pre-specified target SBP range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants achieving the initial pre-specified target SBP range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proinflammatory cytokines (IL-1β, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total-PG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in alexithymia (TAS scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in anxiety and depression (HADS scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in post-traumatic distress (IES-R scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in pain intensity perception (NRS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in psychological distress (ET scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Aware of Known and Potential Risks of Infection Associated with Rituximab
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants Using Rituximab Off-Label
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total sensory neuropathy (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional cerebral metabolism of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Skin microvascular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in CGM time in target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline on Beck Depression Inventory (BDI) at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on The Spielberger State-Trait Anxiety Inventory (STAI-X) at 6 weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: SCINEXA score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: definite asthma diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antral cross sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rising levels of the bone resorption marker CTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Normalized hamstring EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of T1 Gd-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gray and white matter volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in white matter microstructure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: functional capacity of neutrophils to S. aureus vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: induction of oxidative burst to S. aureus vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: phenotype activation of different cell types from PBMCs to S. aureus vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: chemokines and cytokines secretions to S. aureus vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: measures of S. aureus antibodies titre in serum to S. aureus vaccine antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Difference Changes in QTcNi Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Difference Changes in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Difference Changes in QTcF Intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to First Morphine Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine Rescue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant hepatitis B infection status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in lipid metabolome signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in ketone signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in amino acid metabolome signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of impaired glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Brief Negative Symptom Scale (BNSS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lille Apathy Rating Scale (patient version) (LARS-p)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional Remission of General Schizophrenia (FROGS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Activation of the intravascular coagulation system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity and Specificity of AI Guided diagnostics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Academic achievement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Child behavior at school
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of patients with fistula improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Participants with ≥ 50% Decrease in Urticaria Activity Score (UAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of vaginal swab outcomes to endocervical swab outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in Hemoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change from baseline total daily energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Non-exercise activity thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Physiological evaluation of iFR-guided intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End-tidal carbon dioxide (EtCO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients With Modified Rankin Scale (mRS) Score 0-2 at 90 Days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Subjects With Serious Adverse Events Within 7 Days
Endpoint domain: Adverse events/effects
Primary endpoint: 0-24 Hour AUC Leucine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Leucine CMax 0-24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum vitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum and cervical immunoinflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bacterial vaginosis recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from Baseline in Bergs balance scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhancement in axilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who receive neuromuscular blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Peak Bicarbonate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Minimum effective volume of 0.375% bupivacaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGM-measured time in the target range 70-180mg/dl (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Triglyceride Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of hemi-diaphragmatic palsy
Endpoint domain: Adverse events/effects
Primary endpoint: Other allergic rhinitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to hemostasis (TTH) after index procedure (min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: serum creatine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum myoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of root canals in mandibular anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: number of roots in mandibular anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: root canal configuration in mandibular anterior teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of subjects with device related serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to void
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical staff satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Plasma Concentration [Cmax] of ANAVEX2-73
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve [AUC] of ANAVEX2-73
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratio of complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of primary teeth with control necrotic pulp by clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Percentage of primary teeth with control necrotic pulp by radiographic examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Incidence of related non expected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ocular Comfort Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Reporting Positive Oncogenic HPV DNA Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Any Cytological Abnormalities in Cervical Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Referral to Colposcopy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Leaflet Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood glucose correlation coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pin tract infection
Endpoint domain: Adverse events/effects
Primary endpoint: C-Reactive Protein evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Kidney graft rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of polyps in the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mineralization Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root Canal Obliteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Internal Root Resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mastectomy Flap Necrosis
Endpoint domain: Adverse events/effects
Primary endpoint: Apnea-Hypopnea Index (AHI) severity agreement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle
Endpoint domain: Adverse events/effects
Primary endpoint: Recommended Phase II Dose (RP2D) of Gemcitabine in Combination With Pembrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post surgical primary repair outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak paclitaxel plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of ulcer closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Repolarization (QTc and TP-e Intervals)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Selumetinib Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selumetinib AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Selumetinib AUC(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antigen specific B-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit
Endpoint domain: Life impact
Endpoint subdomain: Need for further intervention
Primary endpoint: Modified Behaviour Pain Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referral Rates for Substance Abuse Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Referral Rates for HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of suture abscess or other wound related complication
Endpoint domain: Adverse events/effects
Primary endpoint: Medicines adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Operation of the NMS
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: presence of mutations/polymorphisms in genes SERPINA1, Ermani and KPNB1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in lifting of lax tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pp65 and/or IE-1 specific CMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Patients With a Toxic Event
Endpoint domain: Adverse events/effects
Primary endpoint: Average Peak Pressure Differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients with Lung Collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of risks
Endpoint domain: Adverse events/effects
Primary endpoint: Urinary electrolyte concentrations and pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Area Under the Curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional status change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Decrease of metabolic syndrome criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subclinical atherosclerosis (measured by cIMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and Tolerability in Terms of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose/dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of recommended Phase II dose
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and Severity of Systemic Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of intravitreal injections of ranibizumab
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain score on the WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: completion of pregnancy beyond 20 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Stoppage of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of the hybrid ablation procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inducibility of sustained VT/VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-operative canalisation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of any postnatal home visits from an FLW
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Immunizations for infants and children
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self-reported health perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Function of the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse events (cerebral infarct, death) in 30 days post-procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Rankin Score at 1 year follow-up
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in motor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melatonin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in parental behavior based on the Stim-Q
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in children's language development based on the CDI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in children's language development based on the E/ROWPVT-4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory dermatomal spread
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Haemostatic efficacy at time of non-surgical bleeding (NSB) event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of treatments with blood product transfusions required to resolve any bleeding event
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Assessment of blood loss during any surgical procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: freedom from recurrent atrial tachyarrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximum Tolerated Dose of Hydroxychloroquine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose of Cobimetinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 8-Week Disease Control Rate (DCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete resolution of pancreatic cyst lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in plasma NT-proBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Microbiota-derived uremic toxin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Reduction From Baseline in Menstrual Blood Loss (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responses to acoustic startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prepulse inhibition of acoustic startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Subjects Achieving a 70-point Decline in CDAI Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes